Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran

被引:2
|
作者
Mohsenzadeh, Pooran [1 ]
Ardekani, Ali [2 ]
Poustchi, Hossein [3 ]
Mohammadi, Zahra [3 ]
Abdipour Mehrian, Seyed Reza [1 ,2 ]
Bazrafshan Drissi, Hamed [4 ]
Rahimian, Zahra [5 ]
Taherifard, Erfan [1 ]
Nabavizadeh, Ali [5 ]
Kamalipour, Alireza [6 ]
Mesgarpour, Bita [7 ]
Malekzadeh, Fatemeh [8 ]
Molavi Vardanjani, Hossein [9 ]
机构
[1] Shiraz Univ Med Sci, Sch Med, MPH Dept, Shiraz, Iran
[2] Shiraz Univ Med Sci, Inst Hlth, Hlth Policy Res Ctr, Shiraz, Iran
[3] Univ Tehran Med Sci, Digest Dis Res Inst, Liver & Pancreatobiliary Dis Res Ctr, Tehran, Iran
[4] Shiraz Univ Med Sci, Sch Med, Dept Cardiol, Shiraz, Iran
[5] Shiraz Univ Med Sci, Student Res Comm, Shiraz, Iran
[6] Univ Calif San Diego, Shiley Eye Inst, Hamilton Glaucoma Ctr, Dept Ophthalmol, San Diego, CA 92103 USA
[7] Natl Inst Med Res & Dev NIMAD, Res & Technol, Tehran, Iran
[8] Univ Tehran Med Sci, Shariati Hosp, Digest Dis Res Ctr, Digest Dis Res Inst, Tehran, Iran
[9] Shiraz Univ Med Sci, Res Ctr Tradit Med & Hist Med, Sch Med, MPH Dept, Shiraz, Iran
关键词
Polypharmacy; Medication adherence; Cardiovascular diseases; Prevalence; OLDER-ADULTS;
D O I
10.1186/s12872-022-02872-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Polypharmacy in patients with cardiovascular diseases (CVDs) has been linked to several adverse outcomes. This study aimed to investigate the pattern of medication use and prevalence of polypharmacy among CVDs patients in Iran. Method We used the baseline data of the Pars cohort study (PCS). The participants were asked to bring their medication bags; then, the medications were classified using the Anatomical Therapeutic Chemical classification. Polypharmacy was defined as using five or more medications concurrently. Poisson regression modeling was applied. The adjusted prevalence ratios (PR) and its 95% confidence interval (CI) were estimated. Results Totally, 9262 participants were enrolled in the PCS, of whom 961 had CVDs. The prevalence of polypharmacy in participants with and without CVDs was 38.9% and 7.1%, respectively. The highest prevalence of polypharmacy (51.5%) was among obese patients. Abnormal waist-hip ratio (PR: 2.79; 95% CI 1.57-4.94), high socioeconomic status (PR: 1.65; 95% CI 1.07-2.54), tobacco-smoking (PR: 1.35; 95% CI 1.00-1.81), patients with more than three co-morbidities (PR: 1.41; 95% CI 1.30-1.53), high physical activity (PR: 0.66; 95% CI 0.45-0.95), use of opiate ever (PR: 0.46; 95% CI 0.26-0.82), and healthy overweight subjects (PR: 0.22; 95% CI 0.12-0.39) were associated with polypharmacy. Cardiovascular drugs (76.1%), drugs acting on blood and blood-forming organs (50.4%), and alimentary tract and metabolism drugs (33.9%) were the most frequently used drugs. Agents acting on the renin-angiotensin system were the mostly used cardiovascular system drugs among men and those above 60 years old, while beta-blocking agents were mostly prevalent among cardiovascular system drugs in women with CVDs. Conclusion Given the high prevalence of polypharmacy among CVDs patients, and subsequent complications, programs to educate both physicians and patients to prevent this issue is crucial.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Prevalence and determinants of pericardial effusion in the general population, Results from a population-based cohort study
    Sahiti, F.
    Cejka, V.
    Moser, N.
    Albert, J.
    Frantz, S.
    Gelbrich, G.
    Heuschmann, P. U.
    Stoerk, S.
    Morbach, C.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 100 - 100
  • [32] Intellectual disabilities and risk of cardiovascular diseases: A population-based cohort study
    Cho, In Young
    Koo, Hye Yeon
    Um, Yoo Jin
    Park, Yong-Moon Mark
    Kim, Kyung Mee
    Lee, Chung Eun
    Han, Kyungdo
    DISABILITY AND HEALTH JOURNAL, 2025, 18 (02)
  • [33] Drug Use for Secondary Prevention of Cardiovascular Diseases in Golestan, Iran: Results From the Golestan Cohort Study
    Nalini, Mahdi
    Sepanlou, Sadaf G.
    Pourshams, Akram
    Poustchi, Hossein
    Sharafkhah, Maryam
    Bahrami, Hossein
    Kamangar, Farin
    Malekzadeh, Reza
    ARCHIVES OF IRANIAN MEDICINE, 2018, 21 (03) : 86 - 94
  • [34] Cardiovascular Medication Utilization by Educational Level Among Heart Failure Patients: A Population-Based Cohort Study in the Lazio Region, Italy
    Bargagli, Anna Maria
    Cascini, Silvia
    Marino, Claudia
    Davoli, Marina
    Agabiti, Nera
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 5 - 5
  • [35] Risk of Cardiovascular Disease Among Patients with Sarcoidosis: A Population-Based Retrospective Cohort Study
    Ungprasert, Patompong
    Crowson, Cynthia S.
    Matteson, Eric L.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [36] An evaluation of early medication use for COPD: a population-based cohort study
    Falk, Jamie
    Dik, Natalia
    Bugden, Shawn
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 11 : 3101 - 3108
  • [37] Use of anti-secretory medication: a population-based cohort study
    Lassen, A
    Hallas, J
    de Muckadell, OBS
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (05) : 577 - 583
  • [38] Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers
    Fowler, Helen
    Belot, Aurelien
    Ellis, Libby
    Maringe, Camille
    Luque-Fernandez, Miguel Angel
    Njagi, Edmund Njeru
    Navani, Neal
    Sarfati, Diana
    Rachet, Bernard
    BMC CANCER, 2020, 20 (01)
  • [39] Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers
    Helen Fowler
    Aurelien Belot
    Libby Ellis
    Camille Maringe
    Miguel Angel Luque-Fernandez
    Edmund Njeru Njagi
    Neal Navani
    Diana Sarfati
    Bernard Rachet
    BMC Cancer, 20
  • [40] Are osteoarthritis patients at high risk of cardiovascular disease? Results from a large prospective population-based cohort study
    Hoeven, T. A.
    Leening, M. J. G.
    Bindels, P. J.
    Van Meurs, J. B.
    Franco, O. H.
    Kavousi, M.
    Ikram, M. A.
    Hofman, A.
    Witteman, J. C. M.
    Bierma-Zeinstra, S. M.
    EUROPEAN HEART JOURNAL, 2013, 34 : 174 - 174